This is a Complaint pleading for use in litigation of the title matter. Adapt this form to comply with your facts and circumstances, and with your specific state law. Not recommended for use by non-attorneys.
This is a Complaint pleading for use in litigation of the title matter. Adapt this form to comply with your facts and circumstances, and with your specific state law. Not recommended for use by non-attorneys.
This final rule allows an OTP practitioner to initiate treatment of methadone or buprenorphine via telehealth without an initial in-person exam.
As of March 2021, there were 1,816 OTPs in the United States, and in March 2019, the last year for which data is available, approximately 409,000 patients were receiving methadone treatment at OTPs—the only health care setting where this medication can currently be accessed.
An Opioid Treatment Program (OTP) is defined as “a program or practitioner engaged in opioid treatment of individuals with an opioid agonist medication”.
In 2022, an estimated 3.7% of U.S. adults (9,367,000) needed OUD treatment (Figure) (Table). Among these, 55.2% (5,167,000) received OUD treatment, and 25.1% (2,353,000) received medications for OUD (Figure).
The SOTA advises the OTP leadership about the roles of the DEA, SAMHSA, the SOTA and other relevant State and local entities. SOTAs play a key role in ensuring accessible, high quality, and safe opioid use disorder treatment in opioid treatment programs.
As we cross into 2022, there are approximately 1,900 operating OTPs in 49 states, the District of Columbia, Puerto Rico and the Virgin Islands.
Overview. In 2020, an estimated 2.7 million people aged 12 or older, in the United States had an opioid use disorder (OUD) in the past 12 months—including 2.3 million people with a prescription opioid use disorder.
Under the new rules, patients still have to get methadone at clinics, but if they meet the criteria, they can take weeks' worth of bottles home and get counseling via telehealth, and providers have more leeway in prescribing individual doses.
Federal regulations have limited take-home doses due to concerns about overdose and the persistent rhetoric about misuse and diversion since the drug wars of the 1970s.